BACKGROUND: Salivary ductal carcinoma (SDC) is a high-grade malignancy, and molecular studies show frequent overexpression of human epidermal growth factor receptor 2 (HER2). We reviewed our experience with molecular-targeted therapy using trastuzumab for patients with HER2-positive SDC. PATIENTS AND METHODS: The records of all patients treated with trastuzumab for HER2-tested SDC at The University of Texas MD Anderson Cancer Center between 1997 and 2011 were reviewed. RESULTS: Thirteen patients with SDC overexpressing HER2 were treated with trastuzumab as a single agent or in combination with chemotherapy. Ten of these had 3+ immunohistochemistry or HER2 gene amplification by fluorescence in situ hybridization. Patients underwent therapy in the surgical adjuvant setting (n=2), as a component of combined therapy for advanced disease (n=8), or as single therapy near end of life (n=3). Treatment efficacy via radiographic review for response could not be assessed. CONCLUSION: Trastuzumab should undergo prospective therapeutic clinical trials, in SDC which will likely require international cooperation.
BACKGROUND:Salivary ductal carcinoma (SDC) is a high-grade malignancy, and molecular studies show frequent overexpression of human epidermal growth factor receptor 2 (HER2). We reviewed our experience with molecular-targeted therapy using trastuzumab for patients with HER2-positive SDC. PATIENTS AND METHODS: The records of all patients treated with trastuzumab for HER2-tested SDC at The University of Texas MD Anderson Cancer Center between 1997 and 2011 were reviewed. RESULTS: Thirteen patients with SDC overexpressing HER2 were treated with trastuzumab as a single agent or in combination with chemotherapy. Ten of these had 3+ immunohistochemistry or HER2 gene amplification by fluorescence in situ hybridization. Patients underwent therapy in the surgical adjuvant setting (n=2), as a component of combined therapy for advanced disease (n=8), or as single therapy near end of life (n=3). Treatment efficacy via radiographic review for response could not be assessed. CONCLUSION:Trastuzumab should undergo prospective therapeutic clinical trials, in SDC which will likely require international cooperation.
Authors: Masato Nakaguro; Yuichiro Tada; William C Faquin; Peter M Sadow; Lori J Wirth; Toshitaka Nagao Journal: Cancer Cytopathol Date: 2020-05-18 Impact factor: 5.284
Authors: Nhu Thuy Can; Mark W Lingen; Heather Mashek; James McElherne; Renee Briese; Carrie Fitzpatrick; Annemieke van Zante; Nicole A Cipriani Journal: Head Neck Pathol Date: 2017-07-05
Authors: Donna C Ferguson; Amir Momeni Boroujeni; Tao Zheng; Abhinita S Mohanty; Alan L Ho; Maria E Arcila; Dara S Ross; Snjezana Dogan Journal: Mod Pathol Date: 2021-12-28 Impact factor: 8.209
Authors: Tae Hyung Kim; Mi Sun Kim; Seo Hee Choi; Yang Gun Suh; Yoon Woo Koh; Se Hun Kim; Eun Chang Choi; Ki Chang Keum Journal: Radiat Oncol J Date: 2014-09-30